8legs: Tedros adhanom ghebreyesus

Your Followed Topics

#1 out of 4

WHO calls for rapid, global access to new HIV prevention tools, including lenacapavir.
LEN is a long-acting injectable HIV prevention option gaining regulatory approvals in several countries.
Funding cuts disrupted HIV prevention, treatment, and testing services in 2025.
World AIDS Day theme emphasizes solidarity and investment to protect communities at risk.
WHO stresses integration of HIV services into primary health care for better access.
Global AIDS response shows momentum despite funding challenges and donor gaps.
WHO notes that PrEP access declined as donor funding fell.
WHO aims to end AIDS by 2030 with sustained investment and rights-based care.
Global partners include CIFF, Gates Foundation, and Unitaid to improve LEN access.

Vote 0

#2 out of 439.9K est. views

health23h ago

Bbc.co.uk and 1 more

The WHO warns that fewer than 10% of eligible people can access obesity jabs, signaling a global access gap even as obesity rises toward 2030 projections.
GLP-1 therapies have been added to the WHO's essential medicines list to push wider country-level access.
Obesity is framed by WHO as a chronic disease requiring comprehensive, lifelong care rather than a one-off treatment.
High costs, limited production capacity, and supply-chain constraints are major barriers to universal access to obesity injections.
Patent expirations for semaglutide in 2026 could enable cheaper copies in several countries, potentially expanding supply.
WHO urges voluntary licensing to help expand access to affordable GLP-1 versions of the drug.
GLP-1 therapies work by slowing digestion and increasing fullness, aiding weight loss when paired with lifestyle changes.
Weight regain remains a risk after stopping GLP-1 therapy, with cravings often returning within about a year.
Access to obesity jabs should be paired with healthier environments to support lasting weight management.

Vote 1

#3 out of 4

health23h ago

The World Health Organization conditionally recommends GLP-1 weight loss therapies for adults with obesity as part of long-term obesity care.
The WHO notes obesity affects more than one billion people worldwide and could rise to two billion by 2030.
Access to GLP-1 therapies remains a major barrier, with projections that fewer than 10% who could benefit will receive them by 2030.
The guidance recommends combining weight loss drugs with a healthy diet and physical activity for adults.
The WHO plans to issue guidance for treating obesity in children and adolescents next week.
The WHO notes ongoing access challenges even as GLP-1 therapies become more available worldwide.
Ozempic, Wegovy, Mounjaro, and Zepbound are among the GLP-1 medications referenced in the guidance.
NHS England has faced delays in offering obesity treatments to patients, with only a minority of NHS boards providing the drugs as of August.
Top health guidance emphasizes monitoring and long-term support after completing obesity treatment.
The guidance will shape obesity treatment policy as WHO positions GLP-1 therapies within a comprehensive care framework.

Vote 0

#4 out of 4

health15h ago

Measles outbreaks tripled compared with pre-COVID levels, according to WHO.
About 11 million measles cases were recorded last year, up from 10.4 million in 2023.
England's MMR uptake sits at 88.9%, its lowest in 15 years, with gaps in vaccination coverage.
The MMR vaccine remains the best protection against contracting measles and spreading it.
WHO Director-General Tedros warned measles does not respect borders and requires global action.
Major outbreaks have occurred across regions including the West Midlands, North West and London.
Among the under-protected, 75% live in the African and Eastern Mediterranean regions.
Measles can cause serious complications like blindness, brain swelling and pneumonia.
Experts urge continued vaccination to close immunity gaps and prevent outbreaks.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.